Gland Pharma

When is the next results date for Gland Pharma?

No Upcoming Board Meetings

Has Gland Pharma declared dividend?

Yes, Gland Pharma has declared a dividend of 2000% (₹20 per share) with an ex-date of August 16, 2024. While the dividend yield is 1.23%, total returns have varied, showing negative performance in the short term but a strong positive return of 76.32% over the last two years.

Gland Pharma Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2000%<BR>- Amount per share: 20 per share<BR>- Ex-date: 16 Aug 24<BR><BR>Dividend Yield: 1.23%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -9.24%, the dividend return was 0%, resulting in a total return of -9.24%.<BR><BR>Over the past year, the price return was -10.71%, with a dividend return of 1.06%, leading to a total return of -9.65%.<BR><BR>For the 2-year period, the price return was 74.37%, the dividend return was 1.95%, resulting in a total return of 76.32%.<BR><BR>In the last 3 years, the price return was -42.39%, the dividend return was 0.77%, leading to a total return of -41.62%.<BR><BR>Over the past 4 years, the price return was -47.67%, with a dividend return of 0.62%, resulting in a total return of -47.05%.<BR><BR>In the last 5 years, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, Gland Pharma has declared a significant dividend, but the total returns over various periods show a mixed performance, with negative returns in the shorter terms and a strong positive return over the 2-year period.

Who are the peers of the Gland Pharma?

Gland Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, J B Chemicals, Pfizer, Emcure Pharma, and Wockhardt. Gland Pharma has a good management risk rating but shows below-average growth and a 1-year return of -11.87%, significantly lower than Wockhardt's 174.76%.

Peers: Gland Pharma's peers include Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, J B Chemicals &, Pfizer, Emcure Pharma, and Wockhardt.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Good management risk is found at Divi's Lab., Torrent Pharma, Gland Pharma, J B Chemicals &, Pfizer, Emcure Pharma, and Wockhardt. Below Average growth is noted at Divi's Lab., Torrent Pharma, Gland Pharma, Pfizer, and Emcure Pharma, while Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs. Average growth is present at J B Chemicals &, and the rest. Excellent capital structure is held by Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Gland Pharma, J B Chemicals &, Pfizer, while Good capital structure is noted at Torrent Pharma and Emcure Pharma, and Below Average capital structure is found at Wockhardt.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wockhardt at 174.76%, while Gland Pharma has the lowest at -11.87%. Gland Pharma's return is significantly lower than the highest peer. Additionally, the six-month return is negative for Gland Pharma, Emcure Pharma, and Wockhardt.

Who are in the management team of Gland Pharma?

As of March 2023, Gland Pharma's management team includes Chairman Yiu Kwan Stanley Lau, Managing Director & CEO Srinivas Sadu, and several non-executive and independent directors, totaling nine key members.

As of March 2023, the management team of Gland Pharma includes the following individuals:<BR><BR>1. Yiu Kwan Stanley Lau - Chairman & Independent Director<BR>2. Srinivas Sadu - Managing Director & CEO<BR>3. Qiyu Chen - Non-Executive & Non-Independent Director<BR>4. Udo Johannes Vetter - Non-Executive & Non-Independent Director<BR>5. C S N Murthy - Independent Director<BR>6. Essaji Goolam Vahanvati - Independent Director<BR>7. Naina Lal Kidwai - Independent Director<BR>8. Jia Ai (Allen) Zhang - Non-Executive & Non-Independent Director<BR>9. Yao Fang - Non-Executive & Non-Independent Director<BR><BR>This team comprises a mix of executive and non-executive directors, with several independent directors contributing to the governance of the company.

What does Gland Pharma do?

Gland Pharma Ltd is a large-cap pharmaceutical company, incorporated in 1978, with net sales of ₹14,249 Cr and a net profit of ₹1,865 Cr for the quarter ending March 2025. It has a market cap of ₹31,575 Cr and key metrics include a P/E ratio of 46.00 and a dividend yield of 1.05%.

Overview:<BR>Gland Pharma Ltd is a large-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>Gland Pharma Limited was incorporated as 'Gland Pharma Private Limited' on March 20, 1978, and later renamed to 'Gland Pharma Limited' with a fresh certificate of incorporation issued on April 25, 1995. The most recent quarterly results report net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 14,249 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 1,865 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 31,575 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 46.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 1.05%<BR>- Debt Equity: -0.25<BR>- Return on Equity: 7.63%<BR>- Price to Book: 3.41<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the top shareholders of the Gland Pharma?

The top shareholders of Gland Pharma include Fosun Pharma Industrial Pte. Ltd. with 51.83%, mutual funds with 31.16%, and foreign institutional investors holding 6.9%. The largest public shareholder is Mirae Asset Large & Midcap Fund at 6.78%, while individual investors own 2.99%.

The top shareholders of Gland Pharma include Fosun Pharma Industrial Pte. Ltd, which holds the largest stake at 51.83%. Additionally, mutual funds collectively hold 31.16% of the shares, with 24 different schemes involved. Among foreign institutional investors (FIIs), there are 163 holding 6.9% of the company. The highest public shareholder is Mirae Asset Large & Midcap Fund, which owns 6.78%. Individual investors account for 2.99% of the holdings.

How big is Gland Pharma?

As of 24th July, Gland Pharma Ltd has a market capitalization of 32,804.00 Cr, with recent net sales of 5,616.50 Cr and a net profit of 698.52 Cr.

As of 24th July, Gland Pharma Ltd has a market capitalization of 32,804.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Gland Pharma reported Net Sales of 5,616.50 Cr and a Net Profit of 698.52 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 8,723.84 Cr and Total Assets of 10,610.81 Cr.

Is Gland Pharma overvalued or undervalued?

As of November 7, 2025, Gland Pharma is considered overvalued with a PE ratio of 38.88, an EV to EBITDA of 4.16, and a PEG ratio of 2.72, indicating it is more expensive compared to peers like Sun Pharma and Cipla, and has underperformed the Sensex recently.

As of 7 November 2025, Gland Pharma's valuation grade has moved from very expensive to expensive, indicating a shift in perception regarding its market worth. The company is currently considered overvalued. Key ratios include a PE ratio of 38.88, an EV to EBITDA of 4.16, and a Price to Book Value of 0.32, which suggest that while the company has a low book value relative to its market price, its earnings multiples are high compared to peers.<BR><BR>In comparison to its industry peers, Gland Pharma's PE ratio is higher than Sun Pharma's 35.17 and significantly higher than Cipla's attractive PE of 22.33. Additionally, the PEG ratio of 2.72 indicates that the stock may not be growing fast enough to justify its current price. Recent stock performance shows that Gland Pharma has underperformed the Sensex over the past week and month, which further supports the view that it is overvalued in the current market context.

How has been the historical performance of Gland Pharma?

Gland Pharma's historical performance shows fluctuating financial metrics, with net sales and profits declining from March 2024 to March 2025, despite an increase in total assets. The company experienced a significant recovery in net cash inflow, contrasting with previous outflows.

Answer:<BR>The historical performance of Gland Pharma shows a fluctuating trend in key financial metrics over the past six years.<BR><BR>Breakdown:<BR>Gland Pharma's net sales peaked at 5,664.72 Cr in March 2024 but slightly decreased to 5,616.50 Cr in March 2025. The total operating income followed a similar pattern, reaching 5,664.72 Cr in March 2024 and then declining to 5,616.50 Cr in March 2025. The company's operating profit (PBDIT) also saw a decrease from 1,503.31 Cr in March 2024 to 1,482.53 Cr in March 2025. Profit before tax was 1,062.66 Cr in March 2025, down from 1,132.54 Cr in March 2024, while profit after tax decreased to 698.53 Cr from 772.46 Cr in the previous year. The earnings per share (EPS) fell from 46.90 in March 2024 to 42.39 in March 2025. On the balance sheet, total assets increased to 11,172.85 Cr in March 2025 from 10,610.81 Cr in March 2024, with total liabilities also rising to 11,172.85 Cr. The cash flow from operating activities decreased to 914 Cr in March 2025 from 996 Cr in March 2024, while the net cash inflow for March 2025 was 2,199 Cr, a significant recovery from the outflow of 1,551 Cr in March 2024. Overall, Gland Pharma's financial performance reflects a mix of growth in assets and fluctuations in profitability over the years.

Is Gland Pharma technically bullish or bearish?

As of December 4, 2025, Gland Pharma's technical trend is mildly bearish, supported by bearish MACD readings, Bollinger Bands, and underperformance against the Sensex, despite some mixed signals from KST and daily moving averages.

As of 4 December 2025, the technical trend for Gland Pharma has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the weekly and monthly MACD readings, both indicating a bearish sentiment. The Bollinger Bands also reflect a bearish trend on both time frames. The KST shows a mixed signal with a bullish monthly reading but a mildly bearish weekly signal, while the Dow Theory and OBV both confirm a mildly bearish outlook. The daily moving averages are mildly bullish, but this is overshadowed by the overall bearish indicators. The stock has underperformed against the Sensex over multiple periods, further supporting the bearish stance.

Are Gland Pharma Ltd latest results good or bad?

Gland Pharma Ltd's latest Q3 FY26 results show strong revenue growth of 22.49% and a net profit increase of 36.30%, but declining operating margins and return on equity raise concerns about long-term sustainability. Investors should weigh these mixed signals when assessing the company's performance.

Gland Pharma Ltd's latest results for Q3 FY26 show a mixed performance. On the positive side, the company reported a net profit of ₹279.06 crores, which is a significant increase of 36.30% year-on-year. Revenue also saw a robust growth of 22.49% year-on-year, reaching ₹1,695.36 crores, marking the highest quarterly revenue in its recent history.<BR><BR>However, there are some concerning aspects as well. The operating margin decreased to 19.07%, down 201 basis points from the previous year, indicating pressure on profitability despite the revenue growth. Additionally, the return on equity has declined to 8.27%, which is below historical averages and raises concerns about the company's capital efficiency.<BR><BR>Overall, while the revenue and profit figures are encouraging, the decline in margins and return metrics suggests that Gland Pharma is facing challenges that could impact its long-term sustainability. Investors might want to consider these factors carefully when evaluating the company's performance.

Should I buy, sell or hold Gland Pharma Ltd?

Which are the latest news on Gland Pharma?

Why is Gland Pharma Ltd falling/rising?

As of 17-Mar, Gland Pharma Ltd's stock price is experiencing a rise due to a trend reversal and strong recent financial performance. However, concerns about long-term growth and high valuation persist.

As of 17-Mar, Gland Pharma Ltd's stock price is rising, currently at 1,637.05, with a change of 28.35 (1.76%) upward. This increase follows a trend reversal after four consecutive days of decline, indicating a potential shift in market sentiment. Additionally, the stock has outperformed its sector by 1.48% today, suggesting that it is gaining traction compared to its peers.<BR><BR>Despite the positive movement today, it is important to note that the stock has been underperforming in the short term, with a 1-week decline of 2.94% and a 1-month decline of 10.73%. Furthermore, Gland Pharma is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically indicates a bearish trend. The delivery volume has also decreased significantly, falling by 72.72% compared to the 5-day average, suggesting a decline in investor participation.<BR><BR>On the positive side, the company has reported strong financial results, with a PAT growth of 25.67% over the latest six months and record net sales of Rs 1,695.36 crore. High institutional holdings at 40.56% may provide some stability as these investors often have more resources to analyze the company's fundamentals.<BR><BR>However, there are concerns regarding the company's long-term growth, as its operating profit has declined at an annual rate of -1.16% over the past five years. The stock's valuation appears expensive with a Price to Book Value of 2.8, which is higher than its peers, and while it has generated a return of 5.71% over the past year, its profits have only risen by 22.8%, leading to a PEG ratio of 1.4.<BR><BR>In summary, the rise in Gland Pharma Ltd's stock price today can be attributed to a trend reversal and strong recent financial performance, but it is tempered by concerns over long-term growth and valuation.

Why is Gland Pharma Ltd falling/rising?

As of 18-Mar, Gland Pharma Ltd's stock price is rising to 1,670.00, up 2.13%, driven by strong financial results and outperforming its sector. Positive investor sentiment and recent gains further support the stock's upward trend despite some negative indicators.

As of 18-Mar, Gland Pharma Ltd's stock price is rising, currently at 1,670.00, reflecting a change of 34.85 (2.13%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.86% today, indicating a stronger performance relative to its peers. Additionally, it has been gaining for the last two days, with a total return of 3.81% during this period. The stock also reached an intraday high of Rs 1,704, representing a rise of 4.21%.<BR><BR>Furthermore, the company has reported positive financial results for the quarter ending December 25, with net sales reaching their highest at Rs 1,695.36 crore and PBDIT at Rs 434.88 crore. The high institutional holdings at 40.56% suggest that knowledgeable investors are confident in the company's fundamentals, which can positively influence stock performance.<BR><BR>Despite some negative indicators, such as a decline in delivery volume and the stock being lower than several moving averages, the overall positive financial results and recent price performance contribute to the stock's upward movement.

Why is Gland Pharma Ltd falling/rising?

As of 19-Mar, Gland Pharma Ltd's stock price is at 1,595.00, reflecting a 4.11% decline and underperforming its sector. The stock has consistently trended downward, trading below key moving averages and experiencing reduced investor interest, despite previously reported positive financial results.

As of 19-Mar, Gland Pharma Ltd's stock price is falling, currently at 1,595.00, which reflects a decrease of 68.45 or 4.11%. This decline is evident as the stock has underperformed its sector by 1.96% today and has experienced a trend reversal after two consecutive days of gains. The stock reached an intraday low of Rs 1,591.05, marking a drop of 4.35%.<BR><BR>Over the past week, Gland Pharma has seen a decline of 3.71%, which is worse than the Sensex's drop of 2.40%. The one-month performance shows a significant decrease of 13.14%, compared to the Sensex's 10.05% decline. Year-to-date, the stock is down 7.39%, while the Sensex has decreased by 12.92%. This trend indicates a consistent underperformance relative to the benchmark.<BR><BR>Moreover, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. Investor participation has also fallen, with delivery volume on March 18 dropping by 36.58% compared to the 5-day average, indicating reduced interest from investors. Additionally, the Pharmaceuticals & Drugs sector has declined by 2.11%, contributing to the negative sentiment surrounding Gland Pharma.<BR><BR>Despite some positive financial results reported in December, such as record net sales and significant growth in profit before tax, the overall market conditions and sector performance appear to be weighing heavily on the stock, leading to its current decline.

Why is Gland Pharma Ltd falling/rising?

As of 20-Mar, Gland Pharma Ltd's stock price is rising to 1,620.80, reflecting a 1.47% increase today. However, it has shown negative trends over the past week and month, despite strong financial results, indicating mixed investor sentiment.

As of 20-Mar, Gland Pharma Ltd's stock price is rising, currently at 1,620.80, reflecting an increase of 23.55 (1.47%). This upward movement is in line with the sector's performance today, as the stock touched an intraday high of Rs 1631.5, marking a 2.14% rise. <BR><BR>Despite this daily increase, the stock has shown a negative trend over the past week and month, with declines of 0.43% and 10.99%, respectively. However, the company has reported positive financial results for the latest six months, with a profit after tax (PAT) of Rs 462.74 crore, which has grown by 25.67%. Additionally, net sales reached their highest at Rs 1,695.36 crore, and the profit before depreciation, interest, and taxes (PBDIT) also peaked at Rs 434.88 crore. <BR><BR>The stock's current rise may be supported by these strong financial results and the high institutional holdings at 40.56%, indicating confidence from larger investors who are typically more adept at analyzing company fundamentals. However, it is important to note that Gland Pharma is trading below its moving averages across various time frames, and there has been a significant drop in investor participation, with delivery volume falling by 84.2% compared to the 5-day average. <BR><BR>In summary, while Gland Pharma Ltd is experiencing a rise in stock price today, it faces challenges with declining performance metrics over longer periods and reduced trading activity.

Why is Gland Pharma Ltd falling/rising?

As of 23-Mar, Gland Pharma Ltd's stock price is at 1,607.00, down 1.12%. The decline is due to trading below moving averages, a 3.58% drop in the Pharmaceuticals & Drugs sector, and negative stock performance despite strong quarterly results.

As of 23-Mar, Gland Pharma Ltd's stock price is currently at 1,607.00, reflecting a decrease of 18.2 points or 1.12%. This decline can be attributed to several factors. Firstly, the stock has been trading lower than its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Additionally, the broader sector, Pharmaceuticals & Drugs, has also experienced a decline of 3.58%, which may be impacting investor sentiment towards Gland Pharma.<BR><BR>Despite some positive indicators, such as a significant increase in delivery volume by 148.35% on March 20, the overall performance of the stock over the past week and month has been negative, with declines of 0.11% and 10.84%, respectively. Furthermore, while the company has shown strong quarterly results, including record net sales and growth in profit before tax, these have not been sufficient to counteract the negative trends in both the stock's performance and the sector's performance.<BR><BR>Overall, the combination of lower trading relative to moving averages, sector-wide declines, and recent negative stock performance contributes to the current downward movement in Gland Pharma Ltd's stock price.

Why is Gland Pharma Ltd falling/rising?

As of 24-Mar, Gland Pharma Ltd's stock price is rising to 1,675.70, up 3.95%, driven by strong financial results, low debt, and high institutional holdings. Despite a decline in delivery volume, the stock's performance has outpaced its sector, indicating robust investor confidence.

As of 24-Mar, Gland Pharma Ltd's stock price is rising, currently at 1,675.70, reflecting an increase of 63.75 or 3.95%. This upward movement is supported by several factors. Today, the stock opened with a gain of 2.3% and reached an intraday high of Rs 1,679.95, marking a rise of 4.22%. Additionally, the stock has outperformed its sector by 2.83%, indicating strong relative performance.<BR><BR>The company has reported positive financial results, with net sales reaching their highest at Rs 1,695.36 crore and a significant PBDIT of Rs 434.88 crore. Furthermore, the low debt-to-equity ratio of 0 times suggests a stable financial position, which can be attractive to investors. The high institutional holdings at 40.56% also indicate confidence from larger investors who typically have more resources to analyze the company's fundamentals.<BR><BR>Despite a recent decline in delivery volume by 28.5% against the 5-day average, the stock remains liquid enough for trading, which may contribute to its current price rise. Overall, the combination of positive financial results, strong institutional support, and relative outperformance in today's trading has contributed to the rise in Gland Pharma Ltd's stock price.

Why is Gland Pharma Ltd falling/rising?

As of 25-Mar, Gland Pharma Ltd's stock price is rising to 1,713.00, driven by strong financial results, a low debt-to-equity ratio, and high institutional holdings, despite a slight decline in delivery volume. The stock has outperformed its sector and shows a positive trend with consecutive gains.

As of 25-Mar, Gland Pharma Ltd's stock price is rising, currently at 1,713.00, reflecting an increase of 44.55 (2.67%). This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.78% today and has shown a consecutive gain over the last two days, with a total return of 6.27% during this period. Additionally, the stock reached an intraday high of Rs 1728.3, marking a rise of 3.59%.<BR><BR>Despite a decline in delivery volume by 10.41% against the 5-day average, the stock remains liquid enough for trading, indicating continued interest from investors. Furthermore, Gland Pharma Ltd has reported positive financial results, with net sales reaching their highest at Rs 1,695.36 crore and a significant PBDIT of Rs 434.88 crore. The company's low debt-to-equity ratio and high institutional holdings at 40.56% suggest a stable financial position and confidence from larger investors, which may contribute to the stock's rising price. Overall, these factors collectively support the upward trend in Gland Pharma Ltd's stock price.